Hologic, Inc. (NASDAQ:HOLX) Holdings Decreased by Strs Ohio

Strs Ohio lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,641 shares of the medical equipment provider’s stock after selling 4,401 shares during the quarter. Strs Ohio’s holdings in Hologic were worth $1,903,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Belpointe Asset Management LLC grew its position in Hologic by 18.0% during the first quarter. Belpointe Asset Management LLC now owns 937 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 143 shares in the last quarter. Deseret Mutual Benefit Administrators grew its holdings in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 155 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after acquiring an additional 172 shares in the last quarter. Kinneret Advisory LLC grew its holdings in shares of Hologic by 2.3% during the 1st quarter. Kinneret Advisory LLC now owns 7,867 shares of the medical equipment provider’s stock valued at $604,000 after acquiring an additional 176 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent research reports. Raymond James boosted their target price on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Finally, Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic has a consensus rating of “Hold” and a consensus price target of $87.00.

Insider Activity at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock worth $2,473,443 in the last 90 days. 1.75% of the stock is owned by company insiders.

Hologic Price Performance

NASDAQ HOLX opened at $75.38 on Friday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The company has a fifty day simple moving average of $75.75 and a 200 day simple moving average of $72.57. The company has a market cap of $17.69 billion, a P/E ratio of 35.73, a P/E/G ratio of 2.54 and a beta of 1.00. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. During the same period in the prior year, the company earned $1.07 earnings per share. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. On average, sell-side analysts predict that Hologic, Inc. will post 4.01 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.